01

Facts

"Findings point toward the potential of this drug in pain research as well as the need for further research on the pharmacology of kratom’s constituents, their toxicity and potential value in the treatment of opioid use disorder."

Nora D. Volkow, M.D., director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH), January 2020

Nora Volkow

What is kratom?

Kratom (Mitragyna speciosa) is a plant used for hundreds of years in Asia that can boost energy, reduce anxiety and depression, or act as a natural painkiller. It has gained traction in the U.S. over the past 40+ years.

Watch September 2024 Congressional Briefing on kratom science and policy

Link for December 2023 Congressional Briefing with NIDA Director Volkow

 

 

Learn more

Kratom can provide sedative or stimulant effects, depending on how much is taken.

  • At lower doses, it can increase focus like a cup of coffee, combat fatigue or help with anxiety and depression.
  • At higher doses, it’s a natural pain reliever, making it a safer alternative to opioids.
  • There are also early signs kratom might help with opioid withdrawal.
read more
read less

Why do people use kratom?

Millions of Americans use kratom, mainly for its pain-relieving properties and as a safer alternative to opioids. In fact, surveys suggest that many use kratom to reduce opioid use and manage opioid withdrawal.

“We feel that this is a possible solution to the opioid epidemic, and it could come from nature.”

Christopher R. McCurdy, a kratom researcher, at NIH lecture in April 2022

How is kratom consumed?

Kratom is typically sold in the form of tea, powder, capsules, or in extracts. Historically, people would chew the leaves of the kratom tree.

read more
read less

What are the active compounds in kratom?

Kratom is in the same family as coffee. The two most active compounds in the kratom plant are alkaloids known as mitragynine and 7-hydroxymitragynine.

Learn more
  • Both compounds interact with opioid receptors in the brain to produce stimulant and pain-relieving effects.
  • However, current research demonstrates kratom’s alkaloids do not bind with opioid receptors in the same way that opioids do.
  • A new study found that mitragynine, kratom’s primary alkaloid, does not produce negative, opioid-like respiratory effects even at doses many times higher than those known to be taken by humans.

“While [some receptors] produce good analgesia, they don’t cause respiratory depression, and they’re not addictive when they’re activated. They actually work against that, so it’s possible that there’s a mixture … in mitragynine that is counteracting some of the negative side effects and making these substances safer.”

Jay McLaughlin, professor of pharmacodynamics at the University of Florida, and one of the leading experts on kratom

read more
read less

“This rapidly advancing science is explaining how kratom works, and why its pain relieving and other benefits occur with relatively low levels of abuse, dependence, and harmful decreases in respiration compared to opioids.”

Frontiers in Pharmacology review of more than 100 studies on kratom, February 2022

Download the fact sheet
“Public health is better served by assuring continued access to kratom products by consumers and researchers.”
FRONTIERS IN PHARMACOLOGY REVIEW OF MORE THAN 100 STUDIES ON KRATOM
02

Science

What's the latest research?

In recent years federal agencies and health organizations, including the National Institutes of Health (NIH), have funded more scientific research to fully understand the potential benefits of kratom — and its chemical compounds — as well as its dose-dependent risks.

A new study found that mitragynine, kratom’s primary alkaloid, does not produce negative, opioid-like respiratory effects even at doses many times higher than those known to be taken by humans.

This growing body of research is showing promising results for the positive impacts kratom could provide, including in areas such as opioid use disorder treatment.

Learn more
  • The National Institute on Drug Abuse (NIDA) has committed tens of millions of dollars to researching potential medicinal and therapeutic uses of kratom, including providing non-addictive pain relief, treating opioid and alcohol use disorders, and reducing anxiety and depression.
  • Several other agencies are also conducting research, including the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA) and the World Health Organization (WHO).
read more
read less

What is the potential for abuse?

Scientific research on kratom is ongoing. Current data suggest a significantly lower potential for abuse compared with other powerful pain relievers.

In a survey, Johns Hopkins Medicine researchers concluded kratom has a lower rate of harm than prescription opioids for treating pain, anxiety, depression, and addiction.

“Given the current opioid crisis in the United States, there is an urgent need for therapeutics with unique and novel pharmacological mechanisms for opioid use disorders. Recent investigations into mitragynine, the major alkaloid found in Mitragyna speciosa (Kratom), have identified a novel approach to new therapeutic mechanisms that have not been previously explored.”

read more
read less

What are the risks of kratom?

High doses of kratom can lead to side effects such as dizziness or nausea; however, most side effects appear to be mild.

According to the National Institute on Drug Abuse (NIDA), fatal overdoses from kratom use alone appear to be extremely rare. Reports suggest polysubstance use — the use of multiple drugs — involving kratom can lead to more severe adverse effects, such as death and liver problems.

read more
read less

Is kratom addictive?

Reports of kratom addiction are low. Research suggests that some regular kratom users experience withdrawal symptoms, but these are short-term, manageable and rarely interfere with family, social and work activities. Plus, many kratom consumers say the plant actually helps them withdraw from dependent use of opioid drugs.

“There’s interest in the community to test other products that may serve as harm reduction, for example the use of kratom that is sold as tea and contains a drug molecule that … could be utilized also for decreasing withdrawal and depression.”

Nora D. Volkow, M.D., director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH), May 2022

Nora Volkow
The science and research behind kratom
03

Regulation

Is kratom a controlled substance?

Kratom is not classified as a scheduled substance under the Controlled Substances Act (CSA). The federal government withdrew a proposal to schedule the substance in response to tens of thousands of public comments from kratom consumers and bipartisan members of Congress, including Sens. Cory Booker, Kirsten Gillibrand and Ron Wyden.

Timeline of agency action on kratom

gavel on text

2016

At the recommendation of the Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA) publishes a notice of intent to temporarily schedule kratom under the CSA. Less than two months later, the DEA rescinds its notice after receiving numerous public comments and a bipartisan letter from lawmakers.

kratom in lab

2018

The Department of Health and Human Services (HHS) rescinds its earlier evaluation, saying the substance should not be controlled “temporarily or permanently until scientific research can sufficiently support such an action.”

kratom as pills

2018-Present Day

The National Institute on Drug Abuse (NIDA), in coordination with National Institutes of Health (NIH), awards over $15 million in funding for scientific research on kratom to the University of Florida, University of Virginia, University of Michigan, and other institutions.

people taking notes

2021

The World Health Organization’s (WHO) Expert Committee on Drug Dependence (EDCC) concludes there is insufficient evidence of adverse health effects from kratom that would warrant additional critical review or inclusion in the United Nations’ list of internationally controlled substances.

2022

In a letter to lawmakers in March, HHS Secretary Xavier Becerra says: “We believe that additional data and information are needed to understand the public health impact of kratom in terms of therapeutic benefits as well as safety risk.”

“There is a significant risk of immediate adverse public health consequences for potentially millions of users if kratom or its components are included in Schedule I.”

What are the benefits of kratom regulation?

With no standardized regulations in most states and at the federal level, kratom consumers currently have no protection from bad actors selling adulterated kratom products. Unregulated products can contain dangerous drugs or be mixed with other compounds and contaminants.

Legal regulation provides a safe supply of the substance that must meet strict government standards as well as important safeguards such as age restrictions and ID checks.

“We advocate for the FDA to regulate kratom, which would require testing for impurities and maintaining safe levels of the active chemicals. Otherwise, unregulated products run the risk of unsafe additives and dosing problems.”

Albert Garcia-Romeu, Ph.D., a kratom researcher and professor at the Johns Hopkins University School of Medicine, February 2020

Albert Garcia-Romeu
read more
read less

Why would banning kratom be harmful?

Banning kratom possession would criminalize consumers, seriously impede research, and endanger the lives of kratom consumers who rely on the product for pain relief or to help manage opioid withdrawal symptoms.

Furthermore, criminalizing kratom use and possession would turn what should be a public health issue into a criminal justice problem that disproportionately impacts low-income and minority groups and misuses police resources.

“Public health is better served by assuring continued access to kratom products by consumers and researchers.”

Frontiers in Pharmacology review of more than 100 studies on kratom, February 2022

read more
read less
The facts behind kratom regulation
No states have banned kratom since HHS rescinded its recommendation to schedule it.
04

Legislation

What is the Kratom Consumer Protection Act?

The bill standardizes good practices of kratom production and labeling, bans adulteration, and limits artificially elevating the amount of mitragynine and 7-hydroxymitragynine in the product. A federal bill was introduced in 2023 in both the Senate and the House: S. 3039 and H.R. 5905

STATE ACTION
  • Thirteen states have passed a KCPA Bill: Arizona, Colorado, Georgia, Florida, Kentucky, Maryland, Nevada, Oklahoma, Oregon, Texas, Virginia, Utah, and West Virginia. 
  • Six states banned kratom: Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin. However, three of those states - Rhode Island, Vermont and Wisconsin - are currently considering legislation to overturn the ban.
Learn More

The National Black Caucus of State Legislators highlighted the Georgia KCPA as model legislation.

Get the latest updates on kratom
05

Where is kratom regulated?

Check out a state-by-state map showing the status of kratom regulation in the U.S

Check out a state-by-state chart showing kratom regulation in the U.S.

KCPA enacted

KCPA under consideration

Kratom ban currently in effect

No regulations or ban on kratom

State Status Notes
Alabama Restrictive Legislation Enacted Kratom is banned in Alabama: SB 226, passed in 2016, bans the sale and possession of kratom.
Alaska No Legislation or Regulation There was no action on any kratom bill in this Session.
Arizona Consumer Protection Legislation Enacted 2022 Legislative Session: Representative Kaufmann sponsored a strengthening amendment to the KCPA that was originally enacted in 2019. The amended KCPA passed the House on a vote of 38-10 and the Senate on a vote of 20-8. See House Bill 2550
Arkansas Restrictive Legislation Enacted Kratom is banned in Arkansas: The Department of Health issued a ban on kratom in 2015.
California Consumer Protection Legislation Under Consideration There is a kratom regulation bill the AKA does Not support active
Colorado Consumer Protection Legislation Enacted 2022 Legislative Session: Senator Ginal and Representative Sullivan sponsored the KCPA (SB22-120) and the bill passed the Senate on a vote of 32-2, and was amended and passed the House on a vote of 44-20, and is now subject to rulemaking recommendations by the Department of Revenue.
Connecticut No Legislation or Regulation 2022 Legislative Session: The KCPA (HB 6359) was referred for study by the House Health Committee Interim Committee.
Delaware No Legislation or Regulation There was no action on any kratom bill in this Session.
Florida Consumer Protection Legislation Enacted
Georgia Consumer Protection Legislation Enacted The Georgia Legislature passed the KCPA in 2019. See HB 551
Hawaii Consumer Protection Legislation Under Consideration 2022 Legislative Session: Speaker Seiki and Senate President Korchi sponsored the KCPA (HB 2356 and SB 3307) but were not acted on prior to adjournmenet. The bills will be refiled in the 2023 Session.
Idaho Consumer Protection Legislation Under Consideration There was no action on any kratom bill in this Session.
Illinois Consumer Protection Legislation Under Consideration
Indiana Restrictive Legislation Enacted
Iowa No Legislation or Regulation There was no action on any kratom bill in this Session.
Kansas Consumer Protection Legislation Under Consideration 2022 Legislative Session: The KCPA (HB2056) passed the House on a vote of 97-24, but failed to be acted on by the Senate prior to adjournment.
Kentucky Consumer Protection Legislation Enacted KCPA passed in 2024
Louisiana Consumer Protection Legislation Under Consideration 2022 Legislative Session: Representative Thompson filed a kratom ban bill (HB 382) but the bill was never considered prior to adjournment.
Maine No Legislation or Regulation There was no action on any kratom bill in this Session.
Maryland Consumer Protection Legislation Enacted KCPA passed and signed in 2024
Massachusetts No Legislation or Regulation There was no action on any kratom bill in this Session.
Michigan Consumer Protection Legislation Under Consideration 2022 Legislative Session: Represenative Stone sponsored the KCPA (HB 5477) and the bill passed the House on a vote of 8-19, and is awaiting Senate action.
Minnesota No Legislation or Regulation 2022 Legislative Session: Representatives Gomez and West sponsored the KCPA (HF 4815), but the bill was referred to Interim Study. The bill will be refiled in the 2023 Session.
Mississippi Restrictive Legislation Enacted 2022 Legislative Session: A kratom ban bill by Representative Yancey passed the House (HB681), but died in a Senate Committee. The KCPA sponsored by Sen. Tate (SB 2403) also died in Committee.
Missouri Consumer Protection Legislation Under Consideration 2022 Legislative Session: Representative Christofanelli and Senator Rehder sponsored the KCPA (HB 1667 and SB 774) and passed the Senate on a vote of 32-2 and the House on a vote of 106-31. The Governor vetoed the KCPA on July 1, 2022 in part on the claim by the FDA that kratom is federally illegal. The KCPA will be refiled in the 2023 Session
Montana No Legislation or Regulation There was no action on any kratom bill in this Session.
Nebraska No Legislation or Regulation There was no action on any kratom bill in this Session.
Nevada Consumer Protection Legislation Enacted The Board of Pharmacy proposed a ban on kratom despite the existence of the KCPA in Nevada. The Board of Pharmacy formally withdrew its scheduling recommendation and further action is planned in the 2023 Legislative Session to strengthen the KCPA. See AB303
New Hampshire Consumer Protection Legislation Under Consideration 2022 Legislative Session: The KCPA (HB 333) was referrred to Interim Study.
New Jersey Consumer Protection Legislation Under Consideration Active Ban bill in 2024. 2022 Legislative Session: Representative Carol Murphy filed the KCPA (A 4071) and is awaiting action. A ban bill filed by Representative Dancer (A 2642) has not been acted on. Rep. Dancer passed away in July 2022)
New Mexico No Legislation or Regulation There was no action on any kratom bill in this Session.
New York Consumer Protection Legislation Under Consideration 2022 Legislative Session: The KCPA (A 9034) was filed but no action was taken prior to adjournment. The bill will be refiled in the 2023 Session.
North Carolina Consumer Protection Legislation Under Consideration Active KCPA and Ban Bill in 2024
North Dakota No Legislation or Regulation There was no action on any kratom bill in this Session.
Ohio Consumer Protection Legislation Under Consideration 2022 Legislative Session: Representative Lipps filed the KCPA (HB 236) and the bill passed the House on a vote of 82-10. The bill is awaiting Senate action.
Oklahoma Consumer Protection Legislation Enacted The Oklahoma Legislature passed the KCPA in 2021. See HB 2846
Oregon Consumer Protection Legislation Enacted The Oregon Legislature passed the KCPA in 2022. The KCPA (SB1005) passed the Senate 27-2, and the House 55-0. See HB4010
Pennsylvania Consumer Protection Legislation Under Consideration 2022 Legislative Session: Representative Pennycuick sponsored the KCPA (HB 2357) that was amended to impose an age limitation for purchase of kratom at 18 years and younger. The KCPA is now subject to action by the Senate.
Rhode Island Restrictive Legislation Enacted State Ban in Place. In 2024 the House and Senate passed a KCPA ban removal bill but the Governor issued a veto
South Carolina Consumer Protection Legislation Under Consideration There was no action on any kratom bill in this Session.
South Dakota No Legislation or Regulation There was no action on any kratom bill in this Session.
Tennessee Consumer Protection Legislation Under Consideration 2022 Legislative Session: Two bills banning kratom (SB 1390 and HB 1493) failed to pass. The KCPA was offered as a substitute for the House ban bill but was defeated in Committee.
Texas Consumer Protection Legislation Enacted The KCPA passed and signed in Texas
Utah Consumer Protection Legislation Enacted The Utah Legislature passed the KCPA in 2019. See SB 58
Vermont Regstricions enacted by the DOH. No Legislation 2023 the Vermont Dept. of Health agreed to remove kratom from Controlled Substance list. KCPA under consideration
Virginia Consumer Protection Legislation Passed in 2023
Washington Consumer Protection Legislation Under Consideration 2022 Legislative Session: Senator Honeyford filed a kratom ban bill, but agreed to strike it and replace it with the KCPA (SB 5941).
West Virginia Consumer Protection Legislation Passed in 2023
Wisconsin Restrictive Legislation Enacted 2022 Legislative Session: Representative Murphy and Senator Felzkowki sponsored the KCPA (AB 599 and SB 958). The bills were referred to the Wisconsin Controlled Substances Board for an assessment of whether kratom meets the definition under Wisconsin's Controlled Substances Act for scheduling.
Wyoming No Legislation or Regulation There was no action on any kratom bill in this Session.
District of Columbia Restrictive Legislation Enacted There was no action on any kratom bill in this Session.
Guam No Legislation or Regulation There was no action on any kratom bill in this Session.
Puerto Rico No Legislation or Regulation There was no action on any kratom bill in this Session.
Virgin Islands No Legislation or Regulation There was no action on any kratom bill in this Session.

For more information on the most recent legislative action, please contact us here.

Get the latest updates on kratom

I'm interested in:
State
This field is for validation purposes and should be left unchanged.